Clinically Significant Drug Interactions with New Immunosuppressive Agents

被引：0
作者：
Christian Mignat
机构：
[1] Christian Albrechts University of Kiel,Department of Pharmacology
来源：
Drug Safety | 1997年 / 16卷
关键词：
Adis International Limited; Tacrolimus; Sirolimus; Mycophenolate Mofetil; Danazol;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Tacrolimus (FK506), mycophenolate mofetil, sirolimus (rapamycin), gusperimus, and monoclonal antibody preparations are new immunosuppressive agents, some of which are already approved for clinical use, while others are currently undergoing clinical trials. The present article provides an overview of adverse drug interactions between these immunosuppressants and other drugs which may be used concomitantly.
引用
收藏
页码：267 / 278
页数：11
相关论文
共 147 条
[1]  
Campana C(1996)Clinically significant drug interactions with cyclosporin Clin Pharmacokinet 30 141-79
[2]  
Regazzi MB(1995)Mode of action of tacrolimus (FK506): molecular and cellular mechanisms Ther Drug Monit 17 584-91
[3]  
Buggia I(1993)Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation Drugs 46 746-94
[4]  
Thomson AW(1993)Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506 Transplantation 57 1132-3
[5]  
Bonham CA(1994)Interaction between tacrolimus and erythromycin Lancet 344 825-8
[6]  
Zeevi A(1994)Interaction between FK506 and clarithromycin in a renal transplant patient Eur J Clin Pharmacol 47 207-7
[7]  
Peters DH(1991)Interaction between FK506 and clotrimazole in a liver transplant recipient Transplantation 52 1086-35
[8]  
Fitton A(1994)Fluconazole therapy in transplant recipients receiving FK506 Transplantation 57 1521-52
[9]  
Plosker GL(1994)FK 506/Fluconazole interaction enhances FK 506 nephrotoxicity Diabete Metab 20 49-5
[10]  
Sheiner PA(1993)FK506 interaction with danazol Lancet I 1344-8
12345678910